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INTRODUCTION
The intestinal epithelium is faced with the dual task of providing a barrier 
while also allowing nutrient and water absorption, therefore its integrity is 
crucial to maintain physiological function and prevent diseases. Defective 
epithelial barrier function, which can be measured as increased gut 
permeability, has been implicated in the pathogenesis of both irritable bowel 
syndrome (IBS) and inflammatory bowel diseases (IBD). 
Irritable bowel syndrome is a gastrointestinal disorder characterized by 
abdominal pain and altered bowel habit, for which there is no apparent 
structural basis. The diagnosis of irritable bowel syndrome is symptom-based 
according to the Rome criteria, since 2006 Rome III being the most recent. 
“Red flag” symptoms for organic disorders are ruled out by careful history 
taking and thorough physical examination. Rome III defines IBS as recurrent 
abdominal pain or discomfort lasting for at least 3 days per month in the last 3 
months, which is associated with 2 or more of the following characteristics: 
improvement  with defecation, onset associated with change in stool frequency 
or onset associated with change in stool form. Irritable bowel syndrome affects 
5–20% of the population worldwide, thus increasing interest  has recently been 
shown towards its poorly understood pathophysiology and to possible 
therapeutic approaches of the disease. Due to intensive research of recent 
decades, there has been a paradigm shift  in IBS pathophysiology from 
considering it  a purely psychosocial disturbance to finding organic 
backgrounds of the disease. By now, genetic factors, altered “brain-gut axis” - 
both in terms of altered sensory afferent  function and central processing 
resulting in visceral hypersensitivity - abnormal serotonerg neurotransmission, 
altered gut  motility, changes in the gut microflora, stress, intestinal 
hyperpermeability and mucosal immune activation have all been implicated in 
the pathogenesis of IBS. In a preliminary pilot study, it  has been shown that 
fecal supernatants of diarrhea-predominant IBS (IBS-D) patients have a 
substantially higher serine protease activity, similar to that  of patients with 
ulcerative colitis (UC), when compared with healthy subjects or other 
subgroups of IBS patients. Certain serine proteases are signaling molecules 
that cleave protease-activated receptors (PARs), a family of G-protein coupled 
receptors with a widespread distribution. Four members of the PAR family 
have been identified so far in human tissues, of which PAR-2 and 4 are highly 
expressed on intestinal epithelial cells. The primary activating protease of 
PAR-2 is trypsin, however, serine proteases of other endogenous and/or 
bacterial origin are also able to cleave the receptor. Activation of PAR-2 
modulates several gastrointestinal functions, such as motility, ionic exchange, 
paracellular permeability, sensory functions and inflammation. Intracolonic 
but not intraperitoneal administration of the synthetic selective PAR-2 agonist, 
SLIGRL (H-serine-leucine-isoleucine-glycine-arginine-leucine-OH), produces 
delayed visceral hyperalgesia in rats associated with increased paracellular 
permeability. In the intact  epithelium the paracellular space between adjacent 
cells is sealed by dynamically changing tight junctions at  the luminal aspect  of 
the apical junction complex, which forms a selectively permeable barrier and 
is structurally related to the perijunctional actomyosin ring. The integrity of 
the epithelial barrier is dependent upon the contraction of this perijunctional 
actomyosin ring and subsequent physical tension on the tight junction, an 
event  that involves the phosphorylation of myosin light chain (MLC), initiated 
by MLC kinase (MLCK). 
Interestingly, both visceral hypersensitivity and impaired intestinal 
permeability are commonly observed features of IBS. Gut permeability has 
been reported to be enhanced in 50% of post-infectious IBS patients, in 
agreement  with the study showing increased small intestinal permeability in 
both the post-infectious and sporadic forms of IBS, characteristically in the 
diarrhea-predominant subtype, the same subpopulation where increased serine 
protease activity has been detected. In accordance, the report  on the 
“Walkerton epidemic” - a waterborne outbreak of acute gastroenteritis in 
Walkerton, Ontario - proved subtle increase in small intestinal permeability in 
a large number of patients with IBS, however in vitro studies suggest 
enhanced permeability in colonic biopsies of IBS patients compared to healthy 
subjects. Therefore it  seems that gut  permeability in IBS is altered, though the 
data on the subgroup of IBS patients affected and the exact localization of the 
defective barrier are still contradictory. It  is also well established that  impaired 
intestinal barrier function could facilitate the passage of luminal antigens and 
lead to mucosal immune response. Furthermore, there is growing evidence for 
microinflammation of the intestinal and colonic mucosa to play a role in IBS 
pathogenesis. Thus identifying the role of defective mucosal barrier in IBS 
pathomechanism and symptom generation may be an important landmark in 
better understanding of the disease. 
Inflammatory bowel disease is a chronic inflammatory condition of the 
intestines that is characterized by remission and relapses and distills clinically 
into one of the two major subtypes of disease: ulcerative colitis and Crohn‘s 
disease (CD). Current understanding of the underlying pathomechanisms in 
IBD is that  dysregulated mucosal immune response leads to barrier defect 
triggered by antigenic components of the normal commensal microbiota that 
reside within the intestine in a genetically susceptible host. Epithelial barrier 
impairment  is considered important in IBD as it leads to increased luminal 
antigen exposition of the lamina propria, i.e. immune cells, including large 
number of neutrophils, which further aggravate both the inflammatory process 
and the hyperpermeability. Neutrophils are characterized by two major granule 
populations, primary (azurophil) and secondary (specific) granules, formed at 
different  stages of neutrophil maturation. Cathepsin-G (Cat-G), a serine 
protease, makes up approximately 20% of the neutrophil azurophil granule 
proteins and it also plays an important role in neutrophil function during 
inflammatory processes, including degradation of extracellular matrix 
components and cytokines, modulation of integrin clustering on neutrophils 
and direct  chemoattraction of T cells and other leukocytes. Besides trypsin and 
thrombin, proteinase-activated receptor 4 is also activated by the neutrophil 
derived serine protease cathepsin-G. 
There is strong evidence for barrier dysfunction in IBD: hyperpermeability in 
non-involved segments of the intestine of CD patients as well as in first  degree 
relatives has been reported and increased permeability have also been 
associated with an increased risk of relapse. Data are however less abundant 
on paracellular permeability regarding UC. Increase in gut  permeability has 
previously been reported in clinically active UC, which was also shown to 
correlate with disease severity. Still, gut  permeability has not yet been 
evaluated in remission of the disease.
AIMS
The studies were conducted (i) to investigate the origin of elevated fecal serine 
protease activity in IBS-D patients, (ii) to evaluate if this elevated colonic 
luminal serine protease activity may be sufficient to trigger alterations in 
colonic permeability and sensitivity in mice, (iii) to examine the possible 
involvement of PAR-2 activation in this process and (iv) to analyze the 
underlying molecular mechanisms in the tight  junction. We also aimed to (v) 
evaluate whether the high colonic luminal serine-protease activity in UC may 
contribute to increased gut  permeability and (vi) to examine the possible 
involvement of cathepsin-G and PAR-4 in this process. Furthermore, we aimed 
(vii) to measure intestinal and colonic permeability of patients with IBS of the 
diarrhea and of the constipation-predominant subtype in vivo, (viii) to 
investigate possible correlation between increased gut permeability and 
clinical symptoms in IBS-D patients and (ix) to measure gut  permeability in 
patients with ulcerative colitis in remission. 
PATIENTS AND METHODS
1. Patient selection
1.1. Fecal serine proteases in IBS and in UC, their role in mediating increased 
colonic permeability and sensitivity in murine model
Demographic data of the patients enrolled in the study are summarized in 
Table 1. Patients fulfilling the Rome II criteria for IBS (patient  screening was 
carried out  in 2005-2006) participated in the study. All participants provided 
medical history and underwent physical examination. In IBS patients other 
gastrointestinal disorders were excluded by detailed blood and stool analyses, 
serological assays for coeliac disease, lactose–hydrogen breath test  and 
colonoscopy. Active UC was assessed clinically and endoscopically. The study 
protocol was approved by the Ethical Committee of the University of Szeged. 
All subjects provided written and informed consent to participate.
Group Number of patientsAge mean (range) Sex ratio (M/F)
IBS-D 24 49 (19-75) 9/42
IBS-C 18
IBS-A 10
UC 17 41 (18-79) 6/11
INF 23 52 (19-90) 12/11
Healthy subjects 25 44 (30-65) 4/21
Table 1. Demographic data. IBS-D: diarrhea-predominant IBS patients, IBS-C: constipation-
predominant IBS patients, IBS-A: IBS patients with  altered bowel habit, UC: patients with 
ulcerative colitis, INF: patients with acute infectious diarrhea.
1.2. In vivo gut permeability in IBS and in inactive ulcerative colitis
Demographic data of the patients enrolled in the study are summarized in 
Table 2. Thirty patients fulfilling the Rome III criteria for IBS participated in 
the study, none of which related the onset of their symptoms to infectious 
gastroenteritis. According to the Rome III criteria introduced in 2006, 
symptoms are expected to originate 6 months before diagnosis, which is a less 
restrictive timeframe compared to the Rome II criteria (12 weeks of symptoms 
over 12 months). In addition, according to Rome III criteria IBS subtyping 
should be based on stool consistency, which results in four subgroups, namely 
diarrhoea predominant (IBS-D), constipation predominant  (IBS-C), subjects 
with mixed pattern (IBS-M) and unsubtyped IBS (IBS-U). Still, bowel 
subtyping used in Rome II for IBS-D and IBS-C remained acceptable. Other 
gastrointestinal disorders were excluded by detailed blood and stool analyses, 
serological assays for celiac disease, lactose-hydrogen breath test and 
colonoscopy. Patients with inactive ulcerative colitis (partial Mayo score ± 
SEM: 1.3±0.2; CRP (mg/dl) ± SEM: 3.8±1.3) were previously shown to have 
either left-sided colitis or pancolitis. Voluntary subjects, free of any 
gastrointestinal symptoms, served as controls. Patients and voluntary subjects 
with impaired renal function, alcohol consumption, using NSAIDs, 
prokinetics, antihistamines or immunosuppressive agents were excluded from 
the study. UC patients were required to be exclusively on 5-ASA maintenance 
therapy. The study protocol was approved by the Human Investigation Review 
Board, University of Szeged. All subjects provided written and informed 
consent to participate. 
Group Number of patients Age mean (range) Sex ratio (M/F)
IBS-D 18 49 (25-68) 6/12
IBS-C 12 56 (37-65) 2/10
UC 13 47 (29-72) 3/10
Healthy subjects 10 49 (38-65) 2/8
Table 2. Demographic data 
2. Methods
2.1. Fecal samples
Only feces collected in situ, or collected at  home and transported within 1 h 
after defecation to the First Department of Internal Medicine in Szeged, 
Hungary, were used. Samples were stored at -80°C until transportation on dry 
ice to INRA Toulouse, France. Upon arrival, 1g of fecal sample was thawed, 
dissolved, and homogenised in 7ml of Tris buffer, centrifuged (4500 rpm, 10 
min, +4C) and filtered (0.2 µm, Nalgene, (Adventure 16, San Diego, 
California, USA)). The acquired supernatants were used for measuring total 
protease activity, serine protease activity, polymorphonuclear neutrophil 
(PMN) and pancreatic elastase, myeloperoxidase (MPO), calprotectin and 
human secretory leucocyte protease inhibitor (SLPI) activity. 
2.2. Measurement of fecal enzymatic activities
To measure total fecal serine protease activity, supernatants of fecal 
homogenates (25 ml) were incubated with 1 ml of reaction buffer (0.15 M 
NaCl and 20 mM Tris-HCl, pH 8.3) and 1ml of 0.5% (w/v) azocasein (Sigma, 
St Quentin Fallavier, France) at 40°C. The reaction was stopped after 20 
minutes with 1ml of 10% (v/v) trichloracetic acid (TCA, Sigma). Following 
centrifugation, absorption of the clear supernatant was measured at 366 nm. 
Enzymatic activities of the supernatants were normalized to protein content. 
To determine whether protease activity was dependent upon serine proteases, 
measurements were done after preincubation for 30 min with selective serine 
protease inhibitors, AEBSF (4-(2-aminoethyl) benzenesulphonyl fluoride 
hydrochloride) and a mixture of soybean trypsin inhibitor (SBTI) and 
aprotinin (Sigma). Protease activity was expressed as units per milligram of 
protein, standardized against activity elicited by 1U of standard trypsin. 
Pancreatic elastase-1, SLPI, PMN elastase and calprotectin concentrations 
were assayed by ELISA (Schebo-Tech, Giessen, Germany; R& D Systems, 
Lille, France; Immundiagnostik AG, Bensheim, Germany; HyCult 
Biotechnology, Uden, The Netherlands, respectively). Fecal MPO activity was 
measured as described earlier. Cat-G activity was measured in fecal 
supernatants from patients with UC and healthy subjects, using N-succinyl-
Ala-Ala-Pro-Phe p Nitroanilide (Sigma) as a substrate. Enzymatic activity was 
measured at 410 nm for 5 minutes at 37°C.
2.3. Animals
Congenic 6–9-week old male C57BL/6J wild type (Janvier, Le Genest St-Isle, 
France) and PAR-2-deficient  mice (The Jackson Laboratory, Bar Harbor, 
Maine, USA) were used. The genetic status of the PAR-2-deficient mice was 
confirmed by PCR. Mice were housed in polypropylene cages in a light- and 
temperature-controlled room (12 h/12 h cycles; 20±2°C), were fed standard 
pellets (Harlan Teklad, Bicester, Oxon, UK), and water was provided ad 
libitum. The experimental protocols described in the study were approved by 
the local Institutional Animal Care and Use Committee.
2.4. Visceral sensitivity model
Under xylazine/ketamine anaesthesia (both 1.2 mg, subcutaneously), two 
nickel-chrome electrodes were implanted into the abdominal external oblique 
muscle and a third into the abdominal skin, and were exteriorized on the back 
of the neck. On the fifth to seventh postoperative day, colorectal distensions 
were used as noxious stimuli to evaluate visceral hyperalgesia by 
electromyographic (EMG) recording. Under sodium pentobarbital anaesthesia 
(10mg, intraperitoneally), polyethylene perfusion and distension catheters 
(Fogarty catheter for arterial embolectomy, 4F, Edwards Lifesciences, 
Nijmegen, The Netherlands) were inserted into the colon. Animals received 
0.3 ml of fecal supernatants of IBS-D or IBS-C (constipation-predominant 
IBS) patients, of healthy subjects or of IBS-D patients previously incubated 
with serine protease inhibitors, SBTI and aprotinin. The colorectal distension 
procedure started 60 min after the infusion of the supernatants had finished 
with volumes progressively increasing in 0.02 ml steps, from 0 to 0.12 ml, 
each step lasting 10s with 5 min non-distension periods in between. During the 
distension periods, the striated muscle’s EMG activity was recorded and 
analyzed according to Larsson et al. Basal EMG activity was subtracted from 
the EMG activity registered during the periods of distension.
2.5. In vitro permeability model
Mice were sacrificed by cervical dislocation and the distal part of the colon 
was removed. Colonic strips were mounted with a flux area of 0.3 cm2 in 
Easymount Ussing-type chambers (Physiologic Instruments, San Diego, 
California, USA), bathed in Krebs solution and oxygenated at a maintained 
temperature of 37°C. After allowing 15 min for equilibrium, one-fifth of the 
initial volume of the buffer solution (1ml) of the apical compartment  (mucosal 
side) was replaced with physiological saline or supernatants (500ul) and 
fluorescein isothiocyanate (FITC)-labelled dextran (500ul) (4000 Da, 0.022 g/
ml, Sigma). 60 minutes later fluorescent intensity was measured on the serosal 
side of the chamber. Supernatants derived from healthy subjects, from IBS 
patients or from UC patients. IBS-D supernatants were alternatively pre-
incubated with protease-inhibitors soybean trypsin inhibitor (SBTI) and 
aprotinin for 30 minutes on ice and than added to the mucosal side of the 
colonic strip. To assess the potential role of PAR-1, PAR-2 and PAR-4 in the 
effect  of UC fecal supernatants on colonic paracellular permeability, selective 
receptor antagonists were used: PAR1 antagonist  FLLRN (Phe-Leu-Leu-Arg-
Asn, 10µmol/L, Peptides International, Louisville, KY), PAR2 antagonist 
FSLLRY (Phe-Ser-Leu-Arg-Tyr, 10µmol/L, Bachem, Weil am Rhein, 
Germany) and P4-pal10 pepducin (final concentration 1µmol/L) (NeoMPS, 
Strasbourg, France) were added to the mucosal side of the chamber prior to the 
administration of fecal supernatants to the mucosal side. The effect of the 
PAR-4 agonist peptide (Ala-Tyr-Pro-Gly-Lys-Phe-NH2, 50 µmol/L, Sigma) 
was also assessed, as well as the effect  of a selective cathepsin-G inhibitor 
(SCGI): UC fecal supernatants were pre-incubated for 30 minutes on ice with 
the inhibitor (0.2mmol/L) and then the mixture was added to the mucosal side 
of the colonic strip. 
2.6. Immunohistochemistry of pMLC and ZO-1
At 1 and 4 h after the intracolonic infusion of supernatants of IBS-D patients 
or healthy controls, saline, SLIGRL (5 mg) or IBS-D supernatants previously 
incubated with serine protease inhibitors, the mice were sacrificed and the 
distal colon was removed. For both phosphorylated MLC (pMLC) and ZO-1 
immunolabelling, samples were fixed in buffered paraformaldehyde (4%), 
incubated in 30% sucrose (24 h, +4°C), embedded (Tissue Tek medium) and 
frozen in isopentane at  -45°C. Cryostat  sections (7um) were fixed with acetone 
(10 min, -20°C), hydrated in phosphate-buffered saline (PBS) and treated with 
4 mg/ml sodium borohydride (45min, +4°C). Sections were permeabilized 
with PBS–0.5% Triton X-100 and incubated in blocking solution (PBS 
containing 1% bovine serum albumin). For pMLC staining, samples were then 
incubated with goat anti-pMLC antibodies (1/100, SantaCruz, Santa Cruz, 
California, USA) followed by incubation with biotin-conjugated IgG donkey 
anti-goat antibody (1/1000, Interchim, Montlucon, France). Sections were 
rinsed in NaHCO3 (0.1M, pH 8.2) and incubated with FITC-conjugated avidin 
(1/500) diluted in the same solution. For ZO-1 labelling, sections were 
incubated with rabbit  anti-ZO-1 antibodies (1/500, Zymed, San Francisco, 
California, USA) followed by incubation with Alexa fluor 488-conjugated IgG 
donkey anti-rabbit  antibodies (1/2000, Molecular Probes, Cergy-Pontoise, 
France). All sections were mounted in Vectashield HardSet Mounting Medium 
with 4’,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, 
California, USA) and examined under a Nikon 90i fluorescent microscope.
2.7.Western blot for pMLC
Colonic mucosa was collected from mice 1h after intracolonic infusion with 
fecal supernatants of healthy subjects or IBS-D patients, or saline. Proteins 
were extracted with RIPA buffer and quantified. Following the Laemmli 
method, equal amounts of protein extracts were electrophoresed by 12% SDS–
PAGE (sodium dodecyl sulphate–polyacrylamide gel electrophoresis) and then 
electrotransferred onto Hybond-P membrane (GE Healthcare, Bordeaux, 
France). After saturation, the membrane was incubated with anti-pMLC 
primary antibody (1/1000, Biosource, Worcester, Massachusetts, USA) and 
peroxidase-conjugated goat  anti-rabbit  secondary antibody (1/1000, Millipore, 
St Quentin en Yvelines, France). The membrane was developed with 
SuperSignal Reagent (Pierce, Prebieres, France). Integrated density values 
were assessed by ImageJ 1.37 software (NIH, Bethesda, Maryland, USA).
2.8. In vivo permeability measurement with 51Cr-EDTA
To measure intestinal and colonic permeability after an overnight of fasting 
participants emptied their bladders and consumed 51Cr-EDTA (Perkin Elmer 
Life Sciences, Boston, MA, USA) of 1.8 MBq activity dissolved in 100 ml of 
water, followed by 200 ml of standard meal (Nutridrink, Nutricia, Budapest, 
Hungary) containing 300 kcal. Study participants were requested to restrain 
from drinking for 3 hours and from eating for 5 hours. Gut permeability was 
evaluated by measuring 24-hour urine excretion of orally administered 51Cr-
EDTA, where time periods were chosen to relate to permeability within the 
proximal (0-3h) and distal (3-5h) small intestine and the large bowel (5-24h). 
Urinary output was recorded for each period and the radioactivity of 1 ml 
aliquots were counted by a gamma-counter (Packard Cobra, Canberra Packard, 
UK) in duplicates. Gut  permeability was expressed as percentage of urinary 
excretion of the orally administered dose of 51Cr-EDTA (%). 
2.9. Evaluation of symptoms in IBS-D patients 
IBS-D patients were asked to fill out a questionnaire, regarding their clinical 
symptoms at  the time of the permeability measurement. Stool frequency (/
week) and consistency (according to the Bristol stool scale), frequency of 
abdominal pain, distension and bloating (/week), intensity of abdominal pain, 
distension and bloating and quality of life (visual analogue scale /VAS/; %) 
were the symptoms being evaluated and correlated to colonic permeability. 
3. Statistical analysis
All data are presented as means ± SEM. For statistical analysis, Prism 4.0 
(GraphPad, San Diego, California, USA) was used. Multiple comparisons for 
fecal enzymatic activities of different patient groups and integrated optical 
density values of pMLC western blots were analyzed by repeated measures of 
one-way analysis of variance (ANOVA), followed by Tukey’s posttest or 
Kruskal–Wallis posttest  (for MPO activity). Statistical significance for visceral 
hypersensitivity results was established by using two-way ANOVA, followed 
by Bonferroni posttest. In vitro permeability results were analyzed with one-
way ANOVA, followed by Tukey posttest or two-tailed unpaired t test. 
Multiple comparisons for in vivo permeability of different  patient  groups were 
analyzed by repeated measures of one-way ANOVA, followed by Tukey’s 
posttest. Unpaired t-test  was used to evaluate colonic permeability data in 
subgroups of UC patients. Linear regression was applied to establish 
correlation between clinical symptoms and permeability. Statistical 
significance was accepted at p <0.05.
RESULTS
1. Fecal serine protease activity
In healthy subjects the total fecal serine protease activity was 698 U/mg of 
protein. This serine protease activity was significantly greater in IBS-D 
patients (2079 U/mg, p<0.001) and in UC patients (2193 U/mg, p<0.01) 
compared with healthy controls; a similar increase was not present regarding 
the IBS-C, IBS-A subgroups or patients with acute infectious diarrhea (INF). 
Addition of the serine protease inhibitor AEBSF abolished this increased 
protease activity in IBS-D and UC supernatants. A similar inhibition was 
obtained with preincubation with SBTI and aprotinin, two common serine 
protease inhibitors validated for human use. Regarding the potential origin of 
the elevated serine protease activity, no significant difference was observed in 
fecal pancreatic elastase-1 concentration in UC or in any subgroups of IBS 
patients when compared with controls. However, pancreatic elastase-1 
concentration was significantly decreased in INF patients (p<0.05), which 
might  be attributed to the diluted fecal content (i.e. profuse watery diarrhea) 
and restricted diet. PMN-derived elastase had a significantly elevated fecal 
concentration in UC and INF patients (p<0.05), but not  in any subgroup of 
IBS patients. Human fecal SLPI activity showed no significant  difference in 
any of the studied groups of patients when comparing them with control 
subjects. Fecal inflammatory markers, such as human calprotectin and MPO, 
showed a significant increase in UC (p<0.001 and p<0.05, respectively) and 
INF patients (p<0.05 and p<0.001, respectively), but we found no increase in 
any of the IBS subgroups. 
2. Visceral hypersensitivity is triggered by elevated serine protease activity of 
IBS-D supernatants and is dependent on mucosal PAR-2 expression
Intracolonic infusion of fecal supernatants from IBS-D patients administered 
prior to colorectal distensions in mice significantly increased the abdominal 
muscle EMG response (a valid criterion representing nociception) at  low 
distension volumes, namely at 0.02, 0.04 and 0.06 ml, compared with the 
intensity of muscle contractions in animals treated with fecal supernatants of 
control subjects (0.02 ml, 30.6 (5.9) mV/s vs 3.5 (1.7) mV/s; 0.04 ml, 73.4 
(7.9) mV/s vs 18.9 (7.5) mV/s; 0.06 ml, 107.4 (4.4) mV/s vs 53.2 (14.3) mV/s; 
p<0.05, p<0.001 and p<0.001, respectively). Conversely, colonic instillation of 
IBS-C supernatants did not  evoke alteration of visceral sensitivity to colorectal 
distension. Incubation of fecal supernatants from IBS-D patients with serine 
protease inhibitors prior to colonic infusion, prevented the increased EMG 
response to low volumes of distension (0.02 ml, 2.8 (1.4)mV/s, 0.04 ml, 49.8 
(2.9) mV/s; p<0.01, p<0.05, respectively), while protease inhibitors per se had 
no effect (data not  shown). Furthermore, IBS-D supernatants failed to induce 
allodynia or visceral hypersensitivity in PAR-2-deficient mice (0.02 ml, 4.6 
(3.5) mV/s; 0.04 ml, 41.4 (7.0) mV/s; 0.06 m, 59.4 (14.2) mV/s).
3. Increase in colonic paracellular permeability (CPP) is evoked by elevated 
serine protease activity of IBS-D fecal supernatants and is PAR-2 dependent
Administration of fecal supernatants from healthy subjects to the mucosal side 
of the murine colon mounted in Ussing chambers did not  significantly alter 
CPP compared with saline (128% vs. 100%; ns.). In contrast, addition of fecal 
supernatants from IBS-D patients significantly increased the FITC–dextran 
flux compared with the administration of supernatants from healthy subjects or 
saline (192%, p<0.05). Comparatively, supernatants from IBS-C patients 
failed to induce such an increase in colonic permeability (137%; ns.). Previous 
incubation of the supernatants from IBS-D patients with SBTI and aprotinin 
prior to administration significantly decreased the elevated CPP evoked by 
supernatants from IBS-D patients (111% vs. 202%, p<0.01). No increase in 
CPP was observed in response to fecal supernatants from IBS-D patients on 
colonic strips of PAR-2-deficient mice in contrast to their wild-type strain 
(127% vs. 248%, p<0.05).
4. Increased rapid phosphorylation of MLC and delayed redistribution of 
ZO-1 in epithelial cells after mucosal exposure to IBS-D fecal supernatants
One hour after intracolonic infusion with supernatants from IBS-D patients 
there was a pronounced and diffuse labelling of pMLC in epithelial cells, 
similar to that  observed after the infusion of SLIGRL used as a positive 
control for PAR-2 activation, and inhibited by preincubation with serine 
protease inhibitors. Administration of supernatants from healthy subjects or 
saline failed to evoke an increase in pMLC immunostaining, which remained 
restricted to the tight junction area.
Four hours after intracolonic infusion of supernatants from healthy subjects or 
saline, selective immunostaining of the tight  junction protein ZO-1 showed 
labelling that  was restricted to the surface of epithelial cells. In contrast, 
intracolonic infusion of supernatants from IBS-D patients resulted in a marked 
labelling of the intracellular compartment, similarly to that  experienced after 
the infusion of SLIGRL, suggesting intensive internalisation of the protein. 
Previous incubation of fecal supernatants from IBS-D patients with serine 
protease inhibitors prevented the occurrence of a marked intracellular labelling 
of colonocytes. Western blotting showed an increased level of pMLC in the 
colonic mucosa of mice 1h after the intracolonic infusion of supernatants from 
IBS-D patients compared with those infused with supernatants from healthy 
controls (p<0.001). There was no significant difference in the level of pMLC 
in the colonic mucosa of mice that were infused with supernatants from 
healthy subjects or IBS-D supernatants previously incubated with a mixture of 
serine protease inhibitors.
5. Increase in colonic paracellular permeability (CPP) is evoked by 
cathepsin-G of UC fecal supernatants and is PAR-4 mediated
Administration of fecal supernatants from healthy subjects to the mucosal side 
of murine colon mounted in Ussing chambers did not significantly alter CPP, 
as compared with saline (1.58 ± 0.29 vs. 2.00 ± 0.28nmol/h/cm2, ns). In 
contrast, addition of fecal supernatants from UC patients significantly 
increased the FITC-dextran flux compared with supernatants from healthy 
subjects (3.34 ± 0.47nmol/h/cm2; p<0.05) and saline (p<0.01). The addition of 
PAR-1 antagonist  FLLRN (10µmol/L) and PAR-2 antagonist  FSLLRY 
(10µmol/L) did not significantly alter the increased CPP triggered by UC fecal 
supernatants. In contrast, pepducin P4pal-10 significantly reduced the effect  of 
UC fecal supernatants on permeability (1.84 ± 0.20nmol/h/cm2; p<0.05). 
Finally, PAR4 activating peptide (AYPGKFNH2; 50 µmol/L) increased the 
dextran flux across mice colonic epithelium by 199% in comparison with 
vehicle (2.69 ± 0.17 vs. 0.90 ± 0.17nmol/h/cm2, p<0.001). Fecal supernatant 
from patients with UC showed high activity, whereas those from healthy 
subjects presented weak ability to cleave the substrate N-succinyl-Ala-Ala-
Pro-Phe p-Nitroanilide, which is widely used to assess Cat-G activity (28.34  ± 
3.05 vs. 2.02 ± 0.22, p<0.001). Moreover, SCGI decreased enzymatic activity 
in UC supernatants by 43% (16.14 ± 2.02, p<0.01), showing that Cat-G is 
present  in significant  amounts within the lumen in UC, but not in healthy 
subjects. Preincubation of UC fecal supernatants with SCGI abolished the 
effect  of UC fecal supernatants by 77% on paracellular permeability (3.49 ± 
0.53 vs. 2.01 ± 0.30, p<0.05).
6. In vivo gut permeability in IBS and in inactive UC patients
Twenty-four hours urinary excretion of orally administered 51Cr-EDTA 
showed significant increase in the IBS-D and UC groups of patients compared 
to control subjects (3.93±0.43 and 5.39±0.61 vs. 1.97±0.33%, p<0.05 and 
p<0.001 respectively). Gut permeability in IBS-C patients remained as low as 
those of controls showing no significant difference (1.34±0.2%).  Results were 
consistent with the above when time periods were chosen to relate to 
permeability within the proximal (0-3h) and distal (3-5h) small intestine and 
the large bowel (5-24h) during twenty-four-hour urine excretion of orally 
administered 51Cr-EDTA. There was no significant  difference in the proximal 
small intestinal permeability in IBS-D and inactive UC patients compared to 
controls (0.63±0.08 and 0.82±0.09 vs. 0.63±0.1%, respectively). However, 
proximal small intestinal permeability of IBS-C patients was significantly 
decreased compared to controls (0.26±0.05%; p<0.05). Gut permeability did 
not show any significant  difference regarding the distal small intestine in the 
diarrhea- and constipation-predominant subgroups of IBS patients, and 
patients with inactive UC compared to control subjects (0.61±0.12, 0.39±0.08, 
0.83±0.09 vs. 0.43±0.07%, respectively). Colonic permeability of IBS-C 
patients remained as low (0.69±0.12%), as those of control subjects, showing 
no significant difference. On the contrary, colonic permeability of IBS-D 
patients proved to be significantly higher compared to healthy controls 
(2.68±0.35 vs. 1.04±0.18%; p<0.05). Furthermore, colonic permeability of 
patients with inactive UC was also found to be significantly elevated 
compared to control subjects (3.74±0.49 vs. 1.04±0.18%; p<0.001). There was 
no significant  difference in colonic permeability between patients with 
previous endoscopic diagnosis of left-sided colitis or pancolitis (3.26±0.43 vs. 
4.31±0.94%, ns.). 
7. Correlation between increased gut permeability and clinical symptoms in 
IBS-D patients
Stool consistency, frequency of abdominal pain, distension and bloating, 
intensity of abdominal pain, distension and bloating or quality of life did not 
show correlation with increased colonic permeability in IBS-D patients. 
Nevertheless, stool frequency showed good correlation with colonic 
permeability in IBS-D patients (r=0.62; p=0.005). Colonic permeability of 
inactive UC patients did not show correlation with stool frequency.
CONCLUSIONS
To summarize the new results, we have shown that (i) serine protease activity 
can be used as a biomarker to distinguish between IBS-D and acute infectious 
diarrhea, and permits differentiation of IBS-D and UC patients in the absence 
of increased fecal inflammatory markers;  (ii) elevated luminal serine protease 
activity seen in IBS-D patients is sufficient  to trigger an increase in colonic 
permeability and subsequent  visceral hypersensitivity in mice, suggesting 
similar effects in humans; (iii) these effects of luminal serine proteases are 
PAR-2-mediated; (iv) colonic exposure to supernatants from IBS-D patients 
triggers rapid phosphorylation of MLC and delayed internalisation of ZO-1 in 
colonocytes in vivo; (v) elevated serine-protease activity seen in UC is able to 
trigger epithelial barrier disruption; (vi) this barrier disruption is evoked by 
the neutrophil-derived mediator, cathepsin-G via PAR-4 activation; (vii) 
impaired epithelial barrier function is localized to the colon and is restricted to 
the diarrhea-predominant subtype of IBS patients; (viii) increased colonic 
permeability in IBS-D patients correlates with stool frequency and (ix) colonic 
epithelial barrier is also compromised in patients with UC in remission.
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